1 – 80 of 80
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression : observational analysis
(
- Contribution to journal › Article
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
(
- Contribution to journal › Article
-
Mark
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
(
- Contribution to journal › Article
-
Mark
Amyloid-PET imaging predicts functional decline in clinically normal individuals
(
- Contribution to journal › Article
-
Mark
Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
(
- Contribution to journal › Article
-
Mark
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
(
- Contribution to journal › Article
-
Mark
The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App NL−F/NL−F mice
(
- Contribution to journal › Article
-
Mark
Association of MAFLD and MASLD with all-cause and cause-specific dementia : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Digital remote assessment of speech acoustics in cognitively unimpaired adults : feasibility, reliability and associations with amyloid pathology
(
- Contribution to journal › Article
-
Mark
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
(
- Contribution to journal › Article
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer's disease
(
- Contribution to journal › Article
- 2023
-
Mark
The reporting of neuropsychiatric symptoms in electronic health records of individuals with Alzheimer’s disease : a natural language processing study
(
- Contribution to journal › Article
-
Mark
Functional gradients of the medial parietal cortex in a healthy cohort with family history of sporadic Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study
(
- Contribution to journal › Article
-
Mark
Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
(
- Contribution to journal › Article
- 2022
-
Mark
The behavioral variant of Alzheimer’s disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex
(
- Contribution to journal › Article
-
Mark
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
(
- Contribution to journal › Article
-
Mark
Rationale and design of the “NEurodegeneration : Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy
(
- Contribution to journal › Article
-
Mark
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
(
- Contribution to journal › Article
-
Mark
Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic : what is the role of stress perception, stress resilience, and β-amyloid?
(
- Contribution to journal › Article
-
Mark
Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia : a meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease : a literature review
(
- Contribution to journal › Scientific review
-
Mark
Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease
(
- Contribution to journal › Article
- 2021
-
Mark
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Strategies to reduce sample sizes in Alzheimer’s disease primary and secondary prevention trials using longitudinal amyloid PET imaging
(
- Contribution to journal › Article
-
Mark
In vivo tau pathology is associated with synaptic loss and altered synaptic function
(
- Contribution to journal › Article
-
Mark
Tau-related grey matter network breakdown across the Alzheimer’s disease continuum
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
(
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
(
- Contribution to journal › Article
-
Mark
Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology
(
- Contribution to journal › Article
- 2020
-
Mark
Imaging biomarkers in neurodegeneration : Current and future practices
(
- Contribution to journal › Scientific review
-
Mark
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions : implications for cutoffs regarding cognitive impairment
(
- Contribution to journal › Article
-
Mark
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg
(
- Contribution to journal › Scientific review
-
Mark
Relevance of biomarkers across different neurodegenerative
(
- Contribution to journal › Scientific review
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
-
Mark
Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia
(
- Contribution to journal › Article
-
Mark
Quantification of total apolipoprotein e and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
(
- Contribution to journal › Article
- 2019
-
Mark
Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer's disease : Protocol of the BEAT-IT study
(
- Contribution to journal › Article
-
Mark
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
(
- Contribution to journal › Scientific review
-
Mark
Towards a unified protocol for handling of CSF before β-amyloid measurements
(
- Contribution to journal › Article
-
Mark
High occurrence of transportation and logistics occupations among vascular dementia patients : An observational study
(
- Contribution to journal › Article
-
Mark
Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume
(
- Contribution to journal › Article
-
Mark
Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
(
- Contribution to journal › Article
-
Mark
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum
(
- Contribution to journal › Article
- 2018
-
Mark
Slowly progressive dementia caused by MAPT R406W mutations : Longitudinal report on a new kindred and systematic review
(
- Contribution to journal › Article
-
Mark
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation : A 22-year follow-up study
(
- Contribution to journal › Article
-
Mark
Is intracranial volume a suitable proxy for brain reserve? Rik Ossenkoppele
(
- Contribution to journal › Scientific review
-
Mark
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease : a cohort study
(
- Contribution to journal › Article
- 2017
-
Mark
Early- versus late-onset Alzheimer's disease in clinical practice : Cognitive and global outcomes over 3 years
(
- Contribution to journal › Article
-
Mark
Preclinical effects of APOE ϵ4 on cerebrospinal fluid Aβ42 concentrations
(
- Contribution to journal › Article
-
Mark
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)
(
- Contribution to journal › Article
-
Mark
Cerebrovascular and amyloid pathology in predementia stages : The relationship with neurodegeneration and cognitive decline
(
- Contribution to journal › Article
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
(
- Contribution to journal › Article
-
Mark
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease
(
- Contribution to journal › Article
- 2015
-
Mark
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients.
(
- Contribution to journal › Article
-
Mark
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study.
(
- Contribution to journal › Article
- 2013
-
Mark
Plasma tau levels in Alzheimer's disease
(
- Contribution to journal › Letter
-
Mark
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
(
- Contribution to journal › Article
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
- 2011
-
Mark
Predictors of long-term cognitive outcome in Alzheimer's disease.
(
- Contribution to journal › Article
- 2010
-
Mark
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
(
- Contribution to journal › Article